Anthera Raises $33M After Stock Bump on Lupus Data
After getting hammered a month ago on news of a missed primary endpoint in the Phase IIb PEARL-SC study of lupus drug blisibimod, shares of Anthera Pharmaceuticals Inc. rebounded last week when the Hayward, Calif.-based firm released promising data from a subset of patients in the study.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST